Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CTI BIOPHARMA CORP (CTI)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues | 100.0% | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 6.5% | | | 0.0% | 0.0% | 1.4% | 2.4% | 12.0% |
| Gross profit | 93.5% | | | 100.0% | 100.0% | 98.6% | 97.6% | 88.0% |
| Selling, general and administrative | 157.2% | | | 572.6% | 83.9% | 125.0% | 78.9% | 334.8% |
| Research and development | 68.4% | | | 720.7% | 138.7% | 130.7% | 113.2% | 475.5% |
| EBITDA | -144.3% | | | -1177.0% | -120.4% | -154.3% | -84.2% | -717.8% |
| Depreciation | 3.6% | | | 16.3% | 2.3% | 2.9% | 1.4% | 6.1% |
| EBIT | -147.9% | | | -1193.3% | -122.6% | -157.2% | -85.6% | -723.9% |
| Pre-tax income | -172.4% | | | -1196.5% | -111.6% | -162.4% | -92.2% | -749.3% |
| Income taxes | 0.0% | | | -0.1% | -0.1% | -0.6% | -1.6% | -8.3% |
| Net income | -172.4% | | | -1196.4% | -111.8% | -179.0% | -90.6% | -760.9% |
|